Cy5.5

Cy5.5 (Sulfo-Cyanine5.5) is a near-infrared fluorescent dye (Ex=673 nm, Em=707 nm) used to label biological molecules, such as peptides, proteins, and oligonucleotides[1].

Research Areas >> Cancer

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Research Areas >> Metabolic Disease

Research Areas >> Neurological Disease

Cy5.5 contains a free amine group which can be conjugated with a variety of functionalities, including NHS esters, and epoxides. The excitation and emission maximum are 678 and 694 nm, respectively. Cy5.5 has been applied in various fluorescent based experiments. Cy5.5 is a far-red (and near-infrared) emitting dye which is ideal for fluorescence measurements where background fluorescence is a concern. Cy5.5 is cost-effective and its labeling chemistries are easy to perform, making it suitable for potential anti-cancer drug development[1].

Cy5.5-labeled factor VIIa is developed for imagining cancer. Cy5.5 labeled with these targeting proteins specifically localize to the tumor xenografts for at least 14 days but unconjugated Cy5.5 does not localize to any xenografts or organs. This method of imaging anti-tissue factor in the tumor VECs may be useful in detecting primary tumors and metastases as well as monitoring in vivo therapeutic responses[1]. pH/temperature sensitive magnetic nanogels conjugated with Cy5.5-labled lactoferrin (Cy5.5-Lf-MPNA nanogels) are developed as a promising contrast agent for preoperative MRI and intraoperative fluorescence imaging of glioma[2].

[1]. Zhu S, et al. Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. J Drug Target. 2015 Apr;23(3):257-65.

[2]. Jiang L, et al. pH/temperature sensitive magnetic nanogels conjugated with Cy5.5-labled lactoferrin for MR and fluorescence imaging of glioma in rats. Biomaterials. 2013 Oct;34(30):7418-28.

[3]. Lim B, et al. A Unique Recombinant Fluoroprobe Targeting Activated Platelets Allows In Vivo Detection of Arterial Thrombosis and Pulmonary Embolism Using a Novel Three-Dimensional Fluorescence Emission Computed Tomography (FLECT) Technology. Theranostics. 2017 Feb 26;7(5):1047-1061.